Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

139.08 +0.85 (+0.61%)
Official Closing Price Updated: 4:15 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Neurocrine Bioscienc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout. 
Via Chartmill
NASDAQ:NBIX is not too expensive for the growth it is showing.
Don't overlook NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Reasonable Growth, Debt Levels, and a High ROIC Make NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Appealing to Quality Investors.
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a quality stock. 
Via Chartmill
Despite its impressive fundamentals, NASDAQ:NBIX remains undervalued.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), an undervalued stock with good fundamentals. 
Via Chartmill
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
Key Takeaways From Neurocrine Biosciences Analyst Ratings
Via Benzinga
Exploring NASDAQ:NBIX's quality characteristics.
Reasonable growth and debt and a high ROIC for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating. 
Via Chartmill
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.
Investors should take note ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a growth stock that remains attractively priced. 
Via Chartmill
In the world of growth stocks, NASDAQ:NBIX shines as a value proposition.
Looking for growth without the hefty price tag? Consider NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
The market rally appears to be picking up steam. 
Via Investor's Business Daily
A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation
Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report. 
Via Investor's Business Daily
Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive.
Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
NASDAQ:NBIX, a strong growth stock, setting up for a breakout.
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
Via Benzinga
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. 
Via Chartmill
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72. 
Via Investor's Business Daily
NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024
NBIX stock results show that Neurocrine Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
Where Neurocrine Biosciences Stands With Analysts
Via Benzinga
No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win
The company makes Ingrezza, a treatment for the movement disorder known as tardive dyskinesia. 
Via Investor's Business Daily
Sarepta Therapeutics Stock Shows Improved Technical Strength
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. 
Via Investor's Business Daily
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
3 Red-Hot Biotech Rockets Blasting Off in 2024
The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits. 
Via InvestorPlace
Topics Economy
Exposures Economy
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in... 
Via Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza. 
Via Investor's Business Daily
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.